The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Freezing of Gait, 2024Use of Soft Robotic Apparel to Prevent Freezing of Gait in Parkinson’s Disease
Study Rationale: Freezing of gait (FoG) is a disabling walking problem that leads to loss of mobility, falling and poor quality of life in many people with Parkinson’s disease (PD). People with FoG...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Interrogating Novel Defects in Protein Glycosylation in GBA1-associated Parkinson’s Disease
Study Rationale: Sugars are added to proteins in a process called glycosylation. The precise manner in which these sugars are added is critical for the proper function of the resulting glycoproteins...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Use of an Angiotensin-(1-7) Glycopeptide, to Treat Dementia in Parkinson's Disease
Study Rationale: Peptide-based drugs are attractive candidates for treating the cognitive decline associated with Parkinson’s disease (PD) because they demonstrate a robust safety profile and an...
-
Research Grant, 2024(SUPPLEMENT) Investigation of Small Molecules for Rescuing Lysosomal and GBA1 Deficiencies in GBA-associated Parkinson’s Disease
Study Rationale: Individuals with mutations in the GBA1 gene encoding the enzyme β-glucocerebrosidase (GCase) have a higher risk of Parkinson’s disease (PD). Gaucher disease, a rare genetic disease...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024A Clinical Trial to Investigate the Safety of Repeated Subcutaneous Injections of HER-096, a Novel Candidate for Disease-modifying Therapy in Parkinson’s Disease
Study Rationale: sHER-096 is a novel compound that mimics CDNF, a human neurotrophic factor that has shown neuroprotective and neurorestorative properties in an animal model of Parkinson’s disease (PD...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of Selective Ion Channel Inhibitors as a Disease-modifying Therapy for Parkinson’s Disease
Study Rationale: Our aim is to develop an oral medication that will protect the dopamine neurons whose loss is thought to be the cause Parkinson’s disease (PD). Evidence suggests that excessive levels...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.